Generic Name and Formulations:
Trivalent, inactivated, "subunit" influenza vaccine (virus types A and B); contains a total of 45mcg of hemagglutinin per 0.5mL dose; formulation changes annually; susp for IM inj; antibiotic- or preservative-free.
Indications for FLUCELVAX:
Adults and Children:
<4yrs: not established. Each dose is 0.5mL by IM inj once in the deltoid. 4–8yrs: 1 or 2 doses at least 1 month apart (depending on vaccination history as per annual ACIP recommendation). ≥9yrs: 1 dose.
Use current formulation only. Have appropriate medical treatment and supervision readily available. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Latex allergy. Pregnancy (Cat.B). Nursing mothers.
Concomitant vaccines: insufficient data (see full labeling). Immunosuppressants: may get suboptimal response.
Local reactions (eg, pain, erythema), headache, fatigue, myalgia, malaise; syncope.
Single-dose prefilled Luer Lock syringe (0.5mL)—10 (without needles)
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D